A review of aprotinin in orthotopic liver transplantation: Can its harmful effects offset its beneficial effects?

Anesthesia and Analgesia

Volumn 100, Issue 5, 2005, Pages 1248-1255

  Lentschener, Claude ^a,b   Roche, Karine ^a   Ozier, Yves ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Assit Pub Hôpitaux de Paris ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; KALLIKREIN INHIBITOR;

AUTOPSY; BLEEDING; BLOOD CELL; DRUG EFFECT; DRUG HYPERSENSITIVITY; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEMODYNAMICS; HEMOSTASIS; HUMAN; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG EMBOLISM; PRIORITY JOURNAL; REPERFUSION; REVIEW; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

APROTININ; BLOOD LOSS, SURGICAL; ECHOCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; HEMOSTASIS; HEMOSTATICS; HUMANS; LIVER DISEASES; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION;

EID: 17744377992     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000148125.12008.9A     Document Type: Review

References (73)

1. Ozier Y, Pessione F, Samain E, et al. Institutional variability in transfusion practice for liver transplantation. Anesth Analg 2003;97:671-9.
2. Steib A, Freys G, Lehmann C, et al. Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth 2001;48:1075-9.
3. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000;355:1303-9.
4. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043-8.
5. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2000;40:1207-13.
6. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;27:1685-90.
7. Brems JJ, Hiatt JR, Colonna JO, et al. Variable influencing the outcome following orthotopic liver transplantation. Arch Surg 1987;122:1109-11.
8. Mor E, Jennings L, Gonwa TA, et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obst 1993;176:219-27.
9. Ramos E, Dalmau A, Sabate A, et al. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them. Liver transplantation 2003;9:1320-7.
10. Miki C, Iriyama K, Gunson BK, et al. Influence of intraoperative blood loss on plasma levels of cytokines and endotoxin and subsequent graft liver function. Arch Surg 1997;132:136-41.
11. Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage during liver transplantation. Liver Transpl Surg 1997;3:655-9.
12. Navalgund AA, Kang Y, Sarner JB, et al. Massive pulmonary thromboembolism during liver transplantation. Anesth Analg 1988;67:400-2.
13. Baubillier E, Cherqui D, Dominique C, et al. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 1994;15;57:1664-6.
14. Sopher M, Braunfeld M, Shackleton C, et al. Fatal pulmonary embolism during liver transplantation. Anesthesiology 1997;87:429-32.
15. Manji M, Isaac JL, Bion J. Survival from massive intraoperative pulmonary thromboembolism during orthotopic liver transplantation. Br J Anaesth 1998;80:685-7.
16. O'Connor CJ, Roozeboom D, Brown R, Tuman KJ. Pulmonary thromboembolism during liver transplantation: possible association with antifibrinolytic drugs and novel treatment options. Anesth Analg 2000;91:296-9.
17. Fitzsimons MG, Peterfreund RA, Raines DE. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg 2001;92:1418-21.
18. Gologorsky E, De Wolf AM, Scott V, et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 2001;7:783-9.
19. Ramsay MA, Randall HB, Burton EC. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? Liver Transpl 2004;10:310-4.
20. Weng WH, Braunfeld M, Levin P. Recurrent pulmonary embolism during liver transplantation: possible role of hepatitis B immune globulin as a causative agent. Anesthesiology 2002;96:1261-3.
21. Freeman JG, Turner GA, Venables CW, Latner LA. Serial use of aprotinin and incidence of allergic reactions. Cur Med Res Opin 1983;8:559-61.
22. Vusicevic Z, Suskovic T. Acute respiratory distress syndrome after aprotinin infusion. Ann Pharmacother 1997;31:429-32.
23. Bauer J, Futterman S, Dreiling DA. Anaphylactic shock secondary to initial Trasylol administration. Am J Gastroenterol 1971;56:542-4.
24. Steib A, Gengenwin N, Freys G, et al. Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. Br J Anaesth 1994;73:645-8.
25. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997;25:683-8.
26. Porte RJ, Bontempo FA, Knot EA, et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989;47:978-84.
27. Neuhaus P, Bechstein WO, Lefebre B, et al. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989;14:924-5.
28. Mallett S, Rolles K, Cox D, et al. Intraoperative use of aprotinin (Trasylol) in orthotopic liver transplantation. Transplant Proc 1991;23:1931-2.
29. Mallett SV, Cox D, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990;6:986-7.
30. Grosse H, Lobbes W, Frambach M, et al. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss. Thromb Res 1991;63:287-97.
31. Scudamore CH, Randall TE, Jewesson PJ, et al. Aprotinin reduces the need for blood products during liver transplantation. Am J Surg 1995;169:546-9.
32. Groh J, Welte M, Azad SC, et al. Does aprotinin affect blood loss in liver transplantation. Lancet 1992;340:173.
33. Suarez M, Sangro B, Herrero JI, et al. Effectiveness of aprotinin in orthotopic liver transplantation. Semin Thromb Hemost 1993;19:292-6.
34. Patrassi GM, Viero M, Sartori MT, et al. Aprotinin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation. Transfusion 1994;34:507-11.
35. Garcia-Huete L, Sabate A, Domenech P, et al. Aprotinin in orthotopic liver transplantation. Transplant Proc 1995;27:2290-1.
36. Garcia Huete L, Domenech P, Sabate A, et al. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: a randomized clinical study. Hepatology 1997;26:1143-8.
37. Llamas P, Cabrera R, Gomez-Arnau J, Fernandez MN. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin. Haematologica 1998; 83:338-46.
38. Smith O, Hazlehurst G, Brozovic B, et al. Impact of aprotinin on blood transfusion requirements in liver transplantation. Transfus Med 1993;3:97-102.
39. Findlay JY, Rettke SR, Ereth MH, et al. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transpl 2001;7:802-7.
40. Marcel RJ, Stegall WC, Suit CT, et al. Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation. Anesth Analg 1996;82:1122-5.
41. Rentoul TM, Harrison VL, Shun A. The effect of aprotinin on transfusion requirements in pediatric orthotopic liver transplantation. Pediatr Transplant 2003;7:142-8.
42. Milroy SJ, Cottam S, Tan KC, et al. Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation. Br J Anaesth 1995;75:747-51.
43. Molenaar IQ, Begliomini B, Martinelli G, et al. Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology 2001;94:433-8.
44. Findlay JY, Kufner RP. Aprotinin reduces vasoactive medication use during adult liver transplantation. J Clin Anest 2003;15:19-23.
45. Ishitani M, Angle J, Bickston S, et al. Liver transplantation: incidence and management of deep venous thrombosis and pulmonary emboli. Transplant Proc 1997;29:2861-3.
46. Molenaar IQ, Porte RJ. Aprotinin and thromboembolism in liver transplantation: is there really a causal effect? Anesth Analg 2002;94:1367-8.
47. Gosseye S, van Obbergh L, Weynand B, et al. Platelet aggregates in small lung vessels and death during liver transplantation. Lancet 1991;338:532-4.
48. Sankey EA, Crow J, Mallett SV, et al. Pulmonary platelet aggregates: possible cause of sudden perioperative death in adults undergoing liver transplantation. J Clin Pathol 1993;46:222-7.
49. Ellis JE, Lichtor JL, Feinstein SB, et al. Right heart dysfunction, pulmonary embolism, and paradoxical embolization during liver transplantation: a transesophageal two-dimensional echocardiographic study. Anesth Analg 1989;68:777-82.
50. Suriani RJ, Cutrone A, Feierman D, Konstadt S. Intraoperative transesophageal echocardiography during liver transplantation. J Cardiothorac Vasc Anesth 1996;10:699-707.
51. Violi F, Ferro D, Basili S, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 1997;77:44-7.
52. Chedid A, Chadalawada KR, Morgan TR, et al. Phospholipid antibodies in alcoholic liver disease. Hepatology 1994;20:1465-71.
53. Elefsiniotis IS, Diamantis ID, Dourakis SP, et al. Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma: relationship with portal vein thrombosis. Eur J Gastroenterol Hepatol 2003;15:721-6.
54. Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003;52:404-9.
55. Belli L, Romani F, Sansalone CV, et al. Portal thrombosis in cirrhotics: a retrospective analysis. Ann Surg 1986;203:286-91.
56. Violi F, Ferro D, Basili S, et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ 1994;309:239-40.
57. Matsuda J, Saitoh N, Gotoh M, et al. High prevalence of antiphospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995;90:1138-41.
58. Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997;26:554-9.
59. Elias M, Eldor A. Thromboembolism in patients with the "lupus"-type circulating anticoagulant. Arch Intern Med 1984;144:510-5.
60. Samonakis DN, Koutroubakis IE, Sfiridaki A, et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 2004;49:854-8.
61. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996;16:389-402.
62. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;299:236-61.
63. Dalmau A, Sabate A, Koo M, et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transpl 2004;10:279-84.
64. Ritter MD, Owen CA, Bowie WEJ, et al. Evaluation of preoperative haematology-coagulation screening in liver transplantation. Mayo Clinic Proc 1989;64:216-23.
65. Mallett SV, Cox DJA. Thromboelastography (review). Br J Anaesth 1992;69:307-13.
66. Palareti G, Legnani C, Maccaferri M, et al. Coagulation and fibrinolysis in orthotopic liver transplantation: role of the recipient's disease and use of antithrombin III concentrates. Haemostasis 1991;21:68-76.
67. Findlay JY, Rettke SR. Poor prediction of blood transfusion requirements in adult liver transplantations from preoperative variables. J Clin Anesth 2000;12:319-23.
68. Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986;6:79-86.
69. Nunez-Martinez O, De la Cruz G, De Diego A, et al. Liver transplantation for fulminant and subfulminant hepatic failure. Transplant Proc 2003;35:1855-6.
70. Yassen K, Bellamy MC, Sadek SA, Webster NR. Tranexamic acid reduces blood loss during orthotopic liver transplantation. Clin Transplantation 1993;7:453-8.
71. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
72. Kaspar M, Ramsay MAE, Nguyen AT, et al. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 1997;85:281-5.
73. Ozier Y, Steib A, Ickx B, et al. Haemostatic disorders during liver transplantation. Eur J Anaesthesiol 2001;18:208-18.